MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Mylan NV Company Profile (NASDAQ:MYL)

Consensus Ratings for Mylan NV (NASDAQ:MYL) (?)
Ratings Breakdown: 7 Hold Rating(s), 9 Buy Rating(s)
Consensus Rating:Buy (Score: 2.56)
Consensus Price Target: $58.86 (40.77% upside)

Analysts' Ratings History for Mylan NV (NASDAQ:MYL)
Show:
DateFirmActionRatingPrice TargetActions
6/25/2016JPMorgan Chase & Co.Reiterated RatingOverweightView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/13/2016Goldman SachsDowngradeConviction-Buy -> Buy$60.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/4/2016Leerink SwannLower Price TargetOutperform$53.00 -> $51.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/21/2016Wells FargoReiterated RatingMarket PerformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/8/2016BTIG ResearchReiterated RatingBuy$60.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/19/2016ArgusLower Price TargetBuy$65.00 -> $55.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/11/2016Citigroup Inc.Reiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/11/2016GuggenheimReiterated RatingNeutralView Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/11/2016RBC CapitalReiterated RatingHold$60.00 -> $58.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/11/2016Cowen and CompanyLower Price TargetMarket Perform$65.00 -> $55.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/4/2015Morgan StanleyReiterated RatingHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/16/2015BMO Capital MarketsLower Price TargetMarket Perform$46.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/21/2015BarclaysInitiated CoverageEqual Weight$57.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/26/2015Standpoint ResearchInitiated CoverageBuy$70.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/12/2015SusquehannaLower Price TargetPositive$85.00 -> $68.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/7/2015Deutsche BankReiterated RatingBuy$65.00 -> $66.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/7/2015Sanford C. BernsteinLower Price Target$83.00 -> $60.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/18/2015B. RileyInitiated CoverageBuy$85.00 -> $71.23View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/3/2015Raymond JamesInitiated CoverageMarket PerformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/22/2015CRT CapitalBoost Price TargetBuy$68.00 -> $87.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/6/2014S&P Equity ResearchReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/6/2014Bank of AmericaReiterated RatingBuy$68.00 -> $50.23View Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/6/2014ING GroupReiterated RatingBuy$68.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/4/2014Evercore ISIInitiated CoverageHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/8/2014Keefe, Bruyette & WoodsReiterated RatingOutperform$60.00 -> $55.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/28/2014 forward)
Earnings History for Mylan NV (NASDAQ:MYL)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/4/2016        
5/3/2016Q116$0.74$0.76$2.23 billion$2.19 billionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/10/2016Q415$1.27$1.22$2.71 billion$2.49 billionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/30/2015Q315$1.38$1.43$2.79 billion$2.71 billionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/6/2015Q215$0.89$0.91$2.39 billion$2.37 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/5/2015Q115$0.69$0.70$1.87 billionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/2/2015Q414$1.05$1.05$2.07 billion$2.08 billionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/30/2014Q314$1.14$1.16$2.06 billion$2.08 billionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/7/2014Q214$0.73$0.69$1.88 billion$1.84 billionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/1/2014Q114$0.68$0.66$1.80 billion$1.72 billionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/27/2014Q413$0.75$0.78$1.81 billion$1.81 billionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/31/2013Q313$0.79$0.82$1.84 billion$1.77 billionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/1/2013Q2 2013$0.67$0.68$1.73 billion$1.70 billionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/2/2013Q1 2013$0.62$0.62$1.69 billion$1.63 billionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/27/2013Q4 2012$0.64$0.65$1.73 billion$1.72 billionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/25/2012$0.77$0.83ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/26/2012$0.55$0.60ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/26/2012$0.51$0.52ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/21/2012$0.50$0.53ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/26/2011$0.51$0.55ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/27/2011$0.45$0.52ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/3/2011$0.44$0.44ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/24/2011$0.45$0.45ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for Mylan NV (NASDAQ:MYL)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividend History for Mylan NV (NASDAQ:MYL)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Mylan NV (NASDAQ:MYL)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
6/3/2016Joseph C Md MaroonDirectorBuy1,670$44.95$75,066.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/25/2016Robert J CindrichDirectorBuy1,190$42.47$50,539.30View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/12/2016Melina E HigginsDirectorBuy19,900$38.68$769,732.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/6/2016Melina E HigginsDirectorBuy100$38.69$3,869.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/28/2016Melina E HigginsDirectorBuy35,000$42.92$1,502,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/5/2016Robert J CouryChairmanSell217,755$45.96$10,008,019.80View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/31/2016Joseph C Md MaroonDirectorBuy4,337$46.36$201,063.32View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/17/2016Mark W ParrishDirectorBuy1,705$44.00$75,020.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/8/2016Wendy CameronDirectorBuy2,190$45.69$100,061.10View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/3/2016Robert J CindrichDirectorBuy2,187$45.83$100,230.21View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/17/2015John D. SheehanCFOSell34,579$55.03$1,902,882.37View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/15/2015Melina E HigginsDirectorSell8,351$73.08$610,291.08View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/3/2015Anthony MauroInsiderSell13,255$53.15$704,503.25View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/3/2015Heather M BreschCEOSell411,996$53.15$21,897,587.40View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/3/2015Rajiv MalikPresidentSell285,394$53.15$15,168,691.10View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/3/2015Robert J CouryChairmanSell947,119$52.55$49,771,103.45View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/3/2015Rodney L PiattDirectorSell46,000$53.15$2,444,900.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/26/2014John D SheehanCFOSell19,475$57.50$1,119,812.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/25/2014Heather M BreschCEOSell100,000$55.80$5,580,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/25/2014Rajiv MalikPresidentSell120,000$55.78$6,693,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/25/2014Robert J CouryChairmanSell165,700$55.78$9,242,746.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/24/2014Heather M BreschCEOSell80,222$55.86$4,481,200.92View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/24/2014Rajiv MalikPresidentSell84,300$55.86$4,708,998.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/24/2014Robert J CouryChairmanSell105,800$55.88$5,912,104.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/7/2014Melina E HigginsDirectorBuy14,000$52.45$734,300.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/18/2014Neil F DimickDirectorSell5,432$48.26$262,148.32View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/19/2014Neil F DimickDirectorSell5,432$50.81$275,999.92View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/22/2014Rajiv MalikPresidentSell80,000$50.00$4,000,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/14/2014Heather BreschCEOSell75,000$46.07$3,455,250.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/20/2014Neil DimickDirectorSell5,813$53.08$308,554.04View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/14/2014C ToddDirectorSell10,000$53.00$530,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/6/2014Harry KormanCOOSell31,970$54.54$1,743,643.80View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/3/2014Anthony MauroInsiderSell20,000$54.81$1,096,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/3/2014Daniel Rizzo, Jr.CAOSell8,003$55.50$444,166.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/3/2014Douglas LeechDirectorSell10,000$55.40$554,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/2/2014Neil DimickDirectorSell5,813$43.15$250,830.95View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/19/2013Rodney PiattDirectorSell10,000$41.84$418,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/12/2013Daniel Rizzo, Jr.CAOSell70,683$42.04$2,971,513.32View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/12/2013Melina HigginsDirectorBuy5,000$42.03$210,150.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/6/2013Heather M BreschCEOSell160,000$35.35$5,656,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/3/2013Neil F DimickDirectorSell19,994$30.51$610,016.94View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/27/2012Daniel C Rizzo JrCAOSell161,124$27.28$4,395,462.72View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/2/2012Douglas J LeechDirectorSell44,280$25.94$1,148,623.20View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/1/2012Anthony MauroInsiderSell12,301$25.79$317,242.79View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/5/2012Anthony MauroInsiderSell12,296$24.84$305,432.64View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for Mylan NV (NASDAQ:MYL)
DateHeadline
06/27/16 05:15 PMAttentive Stocks in Active Notes- NIKE, Inc. (NYSE:NKE), Mylan N.V. (NASDAQ:MYL), Skullcandy, Inc. (NASDAQ:SKUL) - Seneca Globe
06/27/16 05:15 PMMylan N.V. June 15th Short Interest Update - TheFounders Daily
06/27/16 05:15 PMUpbeat Stocks in Focus- Ecopetrol (NYSE:EC), Mylan N.V. (NASDAQ:MYL), PVH (NYSE:PVH) - Seneca Globe
06/27/16 05:15 PMHC Stocks Review: Neurocrine Biosciences, Inc. (NASDAQ:NBIX), Mylan NV (NASDAQ:MYL) - share market updates (press release)
06/27/16 04:31 PMMylan Launches Generic Version of Glaxo's Avodart in U.S. -
06/27/16 10:08 AMWhy Mylan’s Specialty Segment Reported Strong Q1 Growth -
06/27/16 09:55 AMMylan NV breached its 50 day moving average in a Bearish Manner : MYL-US : June 27, 2016 -
06/27/16 08:07 AMMylan’s Generics Segment: 1Q16 Must-Knows -
06/25/16 04:54 PMMylan NV : Launches Generic Avodart® Capsules
06/24/16 04:02 PMMYLAN N.V. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders -
06/24/16 07:57 AMKrasney Financial LLC Decreased Stake in Mylan N V (NASDAQ:MYL) by $6.28 Million as Shares Declined - Press Telegraph
06/24/16 07:57 AMMylan N.V. (MYL) Pops 2.58% for June 23 - Equities.com
06/23/16 05:51 PMMylan NV : Donates EUR1 Million to the Princess Máxima Center for Pediatric Oncology
06/23/16 10:22 AMMylan Donates €1 Million to the Princess Máxima Center for Pediatric Oncology - [PR Newswire] - The donation from Mylan will support the Princess Máxima Center in its mission of treating and curing children with cancer by enhancing research efforts and supporting patients and their families while at the center for treatment.
06/23/16 08:02 AMStocks Buzz: Sprint Corp (NYSE:S), Mylan NV(NASDAQ:MYL) - NYSE Journal (press release)
06/23/16 08:02 AMHC Stocks Outlines: Bristol-Myers Squibb Co (NYSE:BMY), Mylan NV (NASDAQ:MYL) - share market updates (press release)
06/23/16 08:02 AMAnalysts Rating updates about two Stocks: Pfizer, Inc. (NYSE:PFE) , Mylan N.V. (NASDAQ:MYL) - Street Updates
06/23/16 08:02 AMStock's Ratings to Focus: Johnson & Johnson (NYSE:JNJ) , Mylan N.V. (NASDAQ:MYL) - Street Updates
06/23/16 02:23 AMMylan Says Indian Drug Industry Needs More Transparency From FDA -
06/22/16 10:06 AMPerrigo to sell its vitamins, minerals and supplements business
06/21/16 04:57 PMMylan NV Stock Momentum at Critical Inflection Point - CML News
06/21/16 09:46 AMBRIEF-Mylan NV confirms that Attorney General of Netherlands has rejected request of VEB
06/21/16 09:46 AMMylan NV : Attorney General Rejects VEB's Request Regarding Mylan Shareholder Approval of Meda Transaction
06/20/16 05:12 PMBRIEF-Mylan NV confirms that Attorney General of Netherlands has rejected request of VEB - Reuters
06/20/16 08:54 AMAttorney General Rejects VEB's Request Regarding Mylan Shareholder Approval of Meda Transaction - [PR Newswire] - HERTFORDSHIRE, England, and PITTSBURGH, June 20, 2016 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL) today confirmed that the Attorney General of the Netherlands has rejected the request of the Dutch group VEB to initiate enquiry proceedings at the Enterprise Chamber of the Amsterdam Court of Appeal in respect of VEB's opinion that Mylan's shareholders should approve its recently announced public offer for all shares in Meda Aktiebolag (publ.). Mylan has consistently communicated to the VEB and to its shareholders that under applicable law such shareholder approval is not required. Mylan N.V. launched its recommended public offer to the shareholders of Meda on June 17, 2016 to tender all their shares in Meda to Mylan.
06/20/16 06:14 AMTrader sees limited downside in Mylan -
06/20/16 04:13 AMHC Stocks Overview: Novavax, Inc. (NASDAQ:NVAX), Mylan NV (NASDAQ:MYL) - share market updates (press release)
06/18/16 09:38 AMMylan formalizes Meda acquisition with offer document, acceptance forms
06/18/16 09:38 AMAnalysts: Mylan NV (NASDAQ:MYL) Stock Could Go to 71.00
06/17/16 05:10 PMHC Stocks Reports: Amsurg Corp (NASDAQ:AMSG), Mylan NV (NASDAQ:MYL) - share market updates (press release)
06/17/16 08:08 AMRoundup: Revlon agrees to buy Elizabeth Arden in $870M deal; more
06/17/16 08:08 AMMylan completes acquisition of Renaissance's topicals-focused specialty & generics business
06/16/16 05:30 PMMylan NV : to Commence Meda Offer on June 17
06/16/16 03:37 PM4:37 pm Mylan Labs' public tender offer for all shares of Meda has been approved by the Swedish Financial Supervisory Authority; to commence June 17 -
06/16/16 03:35 PMMylan to Commence Meda Offer on June 17 - [PR Newswire] - The Offer is not being made, and this press release may not be distributed, directly or indirectly, in or into, nor will any tender of shares be accepted from or on behalf of holders in, Australia, Hong Kong, Japan, Canada, New Zealand or South Africa, or any other jurisdiction in which the making of the Offer, the distribution of this press release or the acceptance of any tender of shares would contravene applicable laws or regulations or require further offer documents, filings or other measures in addition to those required under Swedish law (including the Swedish Takeover Rules), Dutch law, United Kingdom law, Danish law, Irish law and U.S. law. Mylan N.V. (NASDAQ, TASE: MYL) today announced that its Offer Document relating to its recommended public offer to the shareholders of Meda Aktiebolag (publ.) to tender all their shares in Meda to Mylan (the "Offer") has been approved by the Swedish Financial Supervisory Authority (Sw: Finans-inspektionen) (the "SFSA") and is available, along with acceptance forms, at medatransaction.mylan.com and www.handelsbanken.se/investeringserbjudande.
06/16/16 09:36 AMStocks Earnings Review: Mylan N.V. (NASDAQ:MYL), Companhia de Saneamento Basico do Estado de Sao Paulo ... - Beacon Chronicle
06/16/16 09:36 AMNoteworthy Analysts Suggestions: Valeant Pharmaceuticals International, Inc. (NYSE:VRX) , Mylan N.V. (NASDAQ:MYL) - Street Updates
06/16/16 09:04 AMTerm Sheet — Thursday, June 16 -
06/15/16 05:19 PMAnalyst Consideration on this Stock: Mylan N.V. (NASDAQ:MYL) - News Oracle
06/15/16 05:19 PMWill You Buy These Stocks? - Unilever N.V. (NYSE:UN), Mylan N.V. (NASDAQ:MYL) - Beacon Chronicle
06/15/16 05:19 PMRoundTable completes sale of topical pharmaceutical business to Mylan NV - PE Hub (subscription) (blog)
06/15/16 04:14 PMMYLAN N.V. Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation -
06/15/16 12:47 PMMylan Completes Acquisition of Renaissance's Leading Topicals-Focused Specialty and Generics Business - [PR Newswire] - HERTFORDSHIRE, England and PITTSBURGH, June 15, 2016 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL) today announced that it has successfully completed the acquisition of the non-sterile, topicals-focused specialty and generics business (the "Business") of Renaissance Acquisition Holdings, LLC ("Renaissance"). The Business brings Mylan an attractive and complementary portfolio and pipeline of branded and generic topical products, an established U.S. sales and marketing infrastructure targeting dermatologists, and a high quality, integrated manufacturing and development platform, including a leading topicals-focused contract development and manufacturing organization. Mylan CEO Heather Bresch commented, "By bringing together the Renaissance topicals business with Mylan's existing assets and the pending addition of Meda and its dermatology portfolio, we will become a leader in this very attractive category.
06/15/16 12:32 PMPerrigo (PRGO) Stock Retreats as Takeover Speculation Fades -
06/15/16 09:56 AMPerrigo Shares Gain After Report Drugmaker Is Close to Deal (1)
06/14/16 05:30 PMU.S. senators introduce bill aimed at getting generic drugs to market - [Reuters] - Four U.S. senators - two Democrats and two Republicans - introduced a bill on Tuesday aimed at preventing big pharmaceutical companies from using safety rules to prevent generic drugs from coming to market. Senators Charles Grassley, chair of the Judiciary Committee, and Patrick Leahy, the top Democrat, are sponsors of the bill along with Senators Mike Lee and Amy Klobuchar, the chair of the antitrust subcommittee and top Democrat, respectively.
06/14/16 05:06 PMPerrigo Shares Gain After Report Drugmaker Is Close to Deal
06/14/16 01:29 PMOpioid overdose drug inspires praise, pricing concerns -
06/14/16 10:06 AMStock Performance to Track: Mylan N.V. (NASDAQ:MYL) - News Oracle
06/13/16 04:56 PMMylan Falls as Wells Fargo Says It May Face Price Hike Scrutiny
About Mylan NV

Mylan NV logoMylan N.V., formerly Mylan Inc., is a global pharmaceutical company, which develops, licenses, manufactures, markets and distributes generic, branded generic and specialty pharmaceuticals. Mylan operates in two segments: Generics and Specialty. The Company's generic pharmaceutical business is conducted primarily in the United States and Canada (collectively, North America); Europe, the Middle East, and Africa (collectively, EMEA); and India, Australia, Japan and New Zealand (collectively, Asia Pacific). Its specialty pharmaceutical business is conducted by Mylan Specialty L.P. (Mylan Specialty). The Company's API business is conducted through Mylan Laboratories Limited (Mylan India), which is included within the Asia Pacific region in its Generics Segment. Mylan provides products to customers in approximately 140 countries and territories.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Drugs - Generic
  • Sub-Industry: Pharmaceuticals
  • Exchange: NASDAQ
  • Symbol: MYL
  • CUSIP: 62853010
Key Metrics:
  • Previous Close: $41.81
  • 50 Day Moving Average: $43.25
  • 200 Day Moving Average: $47.22
  • P/E Ratio: 26.75
  • P/E Growth: 0.63
  • Market Cap: $21.25B
  • Current Quarter EPS Consensus Estimate: $4.95 EPS
Additional Links:
Mylan NV (NASDAQ:MYL) Chart for Tuesday, June, 28, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha